Vaccination against SARS-CoV-2 Does Not Protect against the Development of Anosmia in a Hamster Model-Reference-Cited by-同舟云学术

Vaccination against SARS-CoV-2 Does Not Protect against the Development of Anosmia in a Hamster Model

Published:2023-10-05 Issue:10 Volume:11 Page:1564
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Reyna Rachel A.¹²³⁴^ORCID,Walker Jordyn²³,Mitchell Brooke²³^ORCID,Shinde Divya P.²³⁴,Plante Jessica A.²³^ORCID,Weaver Scott C.²³⁴^ORCID,Plante Kenneth S.²³⁴^ORCID

Affiliation:

1. Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA

2. World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555, USA

3. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA

4. Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA

Abstract

Anosmia, a total or partial loss of the ability to smell, is one of the most frequently documented sequelae of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Persistent anosmia is associated with a decrease in quality of life. Here, we assess the impact of virus lineage and vaccination status on anosmia development in the golden Syrian hamster model. To characterize anosmia driven by current variants, we assessed olfactory function in hamsters infected with SARS-CoV-2 lineages A, BA.2, BA.5, BQ.1, and BQ.1.1 using a buried food detection test. We found that significant anosmia occurs upon infection with all variants with a significant correlation between disease severity and degree of anosmia. Moreover, we found that vaccination with either the Pfizer (BNT16b2) or Moderna (mRNA-1273) mRNA vaccines does not protect against anosmia, despite protection against severe disease.

Funder

National Institutes of Health

University of Texas Medical Branch–Galveston

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/10/1564/pdf

Reference40 articles.

1. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) (2023, March 14). COVID-19 Dashboard. Available online: https://coronavirus.jhu.edu/map.html.

2. Chemosensory Dysfunction in COVID-19: Integration of Genetic and Epidemiological Data Points to D614G Spike Protein Variant as a Contributing Factor;Butowt;ACS Chem. Neurosci.,2020

3. Anosmia as a prominent symptom of COVID-19 infection;Heidari;Rhinology,2020

4. Virological assessment of hospitalized patients with COVID-2019;Wolfel;Nature,2020

5. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study;Lechien;Eur. Arch. Otorhinolaryngol.,2020